Zynteglo
Payments companies reported to CMS as associated with Zynteglo. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Zynteglo, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Zynteglo
These are the largest totals companies reported as associated with Zynteglo. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Andrew Dietz | Los Angeles, CA | Pediatric Hematology-Oncology | $87,750.00 |
| John Agwunobi | Torrance, CA | $32,500.00 | |
| Biree Andemariam | Farmington, CT | Hematology & Oncology | $32,300.00 |
| Christine Duncan | Boston, MA | Pediatric Hematology-Oncology | $23,120.00 |
| Daniel Loes | Roseville, MN | Diagnostic Radiology | $14,572.50 |
| John Levine | New York, NY | Pediatric Hematology-Oncology | $11,220.00 |
| Mitchell Weiss | Memphis, TN | Pediatric Hematology-Oncology | $10,290.00 |
| Julie Kanter Washko | Birmingham, AL | Pediatric Hematology-Oncology | $8,840.00 |
| Robert Lindsley | Boston, MA | Medical Oncology | $8,160.00 |
| Shalini Shenoy | Saint Louis, MO | Pediatric Hematology-Oncology | $8,080.00 |
Prescribed Zynteglo?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.